Business Wire

Hisense Donates Leading Quality Devices to PARIS-SAINT-GERMAIN Endowment Fund, Making the World a Better Place Through Charity

Share

Hisense, a leading technology enterprise worldwide, became a global partner with Paris Saint-Germain in 2020. Since then, benefiting from this partnership, Hisense has gained much recognition and support from consumers and built stronger emotional connections with football fans worldwide. As a socially responsible enterprise, Hisense took a step further and elevated its partnership by donating multiple hi-tech devices to non-profit programs and became a patron of Paris Saint-Germain Endowment Fund.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220423005007/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Cantine Solidaire (Photo: Business Wire)

Hisense Donated TVs to Fully Support and Nurture Youth Development

Hisense donated TVs to the Paris Saint-Germain Endowment Fund; these TVs were used in the Cantine Solidaire organized by the Paris Saint-Germain Endowment Fund in March 2022, where 200 teenagers were welcomed to the Parc des Princes. The event focused on equality, sport, culture, digital world, citizenship, and music with students treated to lunch and sports and leisure activities and a CV workshop.

Sabrina Delannoy, Deputy Director of the Paris Saint-Germain Endowment Fund, commented on this partnership: "We are delighted that the club's partners are interested in our projects and are committed to supporting us. It shows that members of the Paris Saint-Germain family share our values. Hisense is an example for others to follow, we hope to continue working altogether in the long-term."

Hisense to Fulfill Corporate Social Responsibility, Aims to Create a Better Sustainable World

Cédric Audebert, Vice President of Hisense France, said: "As a partner of Paris Saint-Germain, we are very interested in the social initiatives of the Paris Saint-Germain Endowment Fund. Sport is a means of sharing and expressing solidarity, two values that are essential to us. Our goal is to show unstinting support for Paris Saint-Germain Endowment Fund, and we urge all companies to come and join us."

Hisense devotes to charity and sustainable development worldwide, it has donated many high-tech home appliances exclusively for Paris Saint-Germain Endowment Fund programs. As part of the above donation, Hisense donated TVs for "PSG HOLIDAYS," provided better equipment for children to have better training experience; also, Hisense donated a large screen TV for ‘Red & Blue School program’, provided long-term support and better environment for after-school training.

Hisense has been upholding the people-oriented concept, actively supporting charities, focusing on social responsibility and striving to make new contributions to global sustainable development.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Caroline Chen
Hisense PR Team
hisenseglobal@ogilvy.com
+8613922322347

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting27.5.2022 16:00:00 EEST | Press release

LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract Number:e16102 Abstract Title: Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis. The abstract is about the cohort A, stage I of the ongoing global phase Ⅲ trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis (clinicaltrials.gov: NCT04222114). Worldwide, GC is one of the most common cancers, contributing to more than 1 million cases per year and 5.6% of all cancer diagnoses [1]. Approximately 50% of the advanced GC patients will develop

FEELM unveils the world's first ceramic coil disposable pod solution at Vaper Expo UK 202227.5.2022 14:38:00 EEST | Press release

FEELM, the flagship atomization tech brand belonging to SMOORE, today showcased the world's first ceramic coil disposable pod solution series, FEELM Max at Vaper Expo UK 2022 in Birmingham, UK. By launching the solution and showcasing its cutting-edge ceramic coil heating technology, FEELM is introducing ceramic coil to the emerging category of disposable vape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005197/en/ (Photo: Business Wire) As a new category in the ascendant, the disposable vape has been growing in popularity since 2020. The market size of disposable (closed system) vaping product has grown to approximately USD2.125 billion in 2021, accounting for 22.7% of global vaping device market share; and it is expected to increase at a GAGR of over 28% from 2022 to 2026, being the fastest-growing category among all vaping products, according to the estimates of Frost & Suvillian. In 2022, the market size of disp

TYAN Brings Modern HPC Server Platforms for Data Centers at ISC 202227.5.2022 10:00:00 EEST | Press release

TYAN®, an industry-leading server platform design manufacturer and MiTAC Computing Technology Corporation subsidiary, will exhibit its latest HPC platforms powered by 3rd Gen AMD EPYC™ Processors with AMD 3D V-Cache™ technology for data centers deployments at the ISC 2022 event from May 30th to June 1st at booth #D400. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005002/en/ TYAN’s Server Platforms Powered by AMD EPYC 7003 Series Processors Provide the Best Foundation for Data Centers that Can be Tailored to Specific Workloads (Photo: Business Wire) “The amount of data generated by humans and machines has increased exponentially and this requires a steady increase of data center compute performance, therefore, modern data centers need balanced hardware to efficiently manage growing data volumes,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's Server Infrastructure Business Unit. “TYAN’s ser

Mavenir’s Containerized Open vRAN Small Cell Solution Wins Award for Outstanding Contribution to Emerging Technology or Architecture27.5.2022 10:00:00 EEST | Press release

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced to have won the SCF Small Cell Awards 2022 for Outstanding Contribution to Emerging Technology or Architecture, for its design and delivery of the first fully containerized small cell Open Virtualized Radio Access Network (Open vRAN), for indoor and outdoor connectivity. Mavenir’s containerized Open vRAN solution is a first of its kind and combines the interoperability of Open RAN with the portability and flexibility of containers. This small cell solution brings the same future-forward approaches of Open RAN and containerization having significant impacts in macro networks to small cell networks. The deployment of a containerized solution is a significant milestone in the evolution of connectivity, moving away from the physical infrastructure to a digital cloud-based environment. Containers take virtualizati

Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma27.5.2022 00:25:00 EEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom